Merck, Sharpe, and Dohme Announces New Investments in Singapore - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck, Sharpe, and Dohme Announces New Investments in Singapore


ePT--the Electronic Newsletter of Pharmaceutical Technology

Merck, Sharpe, and Dohme (MSD) and Singapore’s Economic Development Board jointly announced plans for significant investments by MSD to improve its existing manufacturing facilities in Singapore, as well as for new manufacturing, marketing, and research activities. MSD plans to invest more than $250 million over the next 10 years. The investments will go towards site improvements at its existing facilities in Tuas, expansion of its biotech operations, and addition of technology capabilities to support new product launches. In addition, MSD will commit to new expenditures of $700 million for local research activities.

In a press release, Dr. Beh Swan Gin, managing director of the Economic Development Board said, “We are encouraged that this will pave the way for Singapore to continue to enhance our capabilities as an integrated global pharmaceutical site in Asia, across manufacturing, R&D and commercial operations.”

MSD has a significant presence in Singapore, with approximately 1500 employees in manufacturing, marketing, sales, and the Translational Medicines Research Center. The total value of MSD’s investments in the area is estimated to be $1.5 billion.


See related Pharm Tech articles:

GSK and Singapore Partner in Green Manufacturing

Report from Asia

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here